← All trials
NCT05182073
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2021
- Primary completion
- Sep 30, 2024
- Completion date
- Feb 29, 2040
- First posted
- Jan 10, 2022
- Last posted
- Oct 24, 2022
- Enrollment
- 168
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fate TherapeuticsLead sponsor
- Fate TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.